EGFR and cancer: Among the identified drugs targeting the MAPK pathway and other related pathways, afatinib and lapatinib are cancer drugs that inhibit tyrosine kinase receptors belonging to the EGFR family, reported by the Reactome pathway database as being involved in MAPK upstream signaling.